- Home
- GROY vs RIGL Comparison
GROY vs RIGL Comparison
Compare GROY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | RIGL |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.1M | 564.7M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GROY | RIGL |
|---|---|---|
| Price | $2.86 | $32.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.90 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.8M | 278.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $145.80 | N/A |
| Revenue Next Year | $60.03 | $12.75 |
| P/E Ratio | ★ N/A | $74.51 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $2.14 | $18.14 |
| 52 Week High | $5.45 | $52.24 |
Technical Indicators
Market Signals| Indicator | GROY | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 62.38 |
| Support Level | $2.69 | $28.14 |
| Resistance Level | $3.86 | $33.09 |
| Average True Range (ATR) | 0.14 | 1.41 |
| MACD | 0.01 | 0.29 |
| Stochastic Oscillator | 31.09 | 75.04 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is principally engaged in acquiring gold-focused royalties, streaming, and similar interests. It is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. The Company operates in Bosnia and Herzegovina, Canada, which generates maximum revenue, the USA, Brazil, and Mexico.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.